共查询到20条相似文献，搜索用时 546 毫秒
1.
猪口蹄疫免疫失败的原因包括疫苗、免疫程序、免疫操作、饲养管理和猪群健康等因素.提高免疫效果,必须提高疫苗质量,制定科学免疫程序,确保免疫密度,提高猪群健康水平等综合防控措施,才能取得良好效果. 相似文献
2.
3.
免疫程序是根据猪群的免疫状态和传染病的流行季节,结合当地疫情而制定的预防接种计划.规模化种猪场必须有适合自己的免疫接种计划,它包括接种的疫病种类、疫(菌)苗种类,接种时间、次数及间隔等内容.本文根据规模化猪场中的猪主要疫病的流行情况、抗体水平制定免疫程序标准. 相似文献
4.
当前,规模化养猪场疫病繁杂,为防止猪群免受传染病危害,制定一套科学合理的免疫程序,对猪群进行免疫至关重要。总结归纳了免疫程序设计的影响因素及注意事项,旨在为规模化养猪场免疫保健程序的制定提供参考。 相似文献
5.
详细论述了规模养猪场制定蓝耳痛免疫策略的方法.首先应用蓝耳病抗体ELISA试验方法,进行猪群抗体水平检测,然后结合猪群在临床上有无繁殖障碍问题,进行猪群的感染状况评估,正确选用疫苗,制定合理的免疫程序. 相似文献
6.
猪免疫谱与免疫程序的制定 总被引：1，自引：0，他引：1
猪的免疫是一个陈旧而又沉重的话题,在中国猪业飞速发展的30年,从来未离开过这个话题,至今仍是热门话题.猪的疾病多,特别是近10多年,新病不断出现,使其可免疫疾病谱多达16种以上,养猪人在如何免疫、怎样安排免疫上惶惶然不知所措;近两年疫病肆虐,猪瘟至今未彻底控制等现象又导致人们对免疫谱与免疫程序的制定产生了广泛的争议.故而,笔者将本人帮助养猪企业制定免疫谱与免疫程序的经验列下,或许会对同仁有所裨益. 相似文献
7.
《养殖与饲料．饲料世界》2014,(11):66-66
参考目标场的免疫程序及所引种猪的免疫记录,根据本场的免疫程序制定适合隔离猪群的科学的免疫程序。
如果所引种的种猪猪瘟疫苗的免疫记录不明或经监测猪群的猪瘟抗体水平不高或不整齐,应立即加大剂量全群补免猪瘟脾淋苗。如果猪瘟先前免疫效果确实,可按新制定的本场免疫程序进行免疫。重点做好蓝耳病病原的检测和疫苗接种工作,而对于国家强制免疫的疫苗要按国家规定执行（如五号病、某些地方的链球菌病等）。 相似文献
8.
9.
10.
规模化猪场免疫程序的设计 总被引：4，自引：0，他引：4
免疫程序是根据猪群的免疫状态和传染病的流行季节，结合当地疫情而制定的预防接种计划。规模化种猪场必须有适合自己的免疫接种计划，它包括接种的疫病种类、疫（菌）苗种类，接种时间、次数及间隔等内容。免疫程序应当根据疫病在本地区及附近地区的发生与流行情况、抗体水平、疫病种类、生产需要、饲养管理方式、疫苗种类与性质、免疫途径以及猪只的用途（种用、肉用）、年龄等方面的因素来制定。免疫程序不能作硬性统一规定，所制定的免疫程序应根据具体情况随时调整。１疫病流行情况猪传染病种类繁多，流行快，分布广。制定免疫程序首先… 相似文献
11.
12.
13.
14.
高致病性禽流感免疫的管理环节 总被引：1，自引：0，他引：1
一 严管疫苗生产环节
兽用生物制品生产厂家多,品种较多,质量不一,免疫效果各异,特别是高致病性禽流感疫苗,由于生产时间较短,疫苗质量不够稳定,副作用较为严重,包装规格单一,技术服务滞后．严重地影响了高致病性禽流感的免疫效果。如有的厂家疫苗生产的批准文号和疫苗产品不相符。有的中试产品或有临时批准文号的疫苗,不按规定范围随意大面积推广,有的同一厂家生产的疫苗,不同批次质量不一,免疫效果差异较大。 相似文献
15.
16.
17.
Transgenic pigs for xenotransplantation for humans] 总被引：1，自引：0，他引：1
H Niemann 《DTW. Deutsche tier?rztliche Wochenschrift》1999,106(4):141-146
Transgenic livestock have been generated via microinjection of DNA-constructs into pronuclei of zygotes. However, efficiency is low and only 1-3% transgenic offspring are to be obtained. Integration of the transgene occurs at random and expression is independent from the number of integrated copies but can be affected by the integration site. To overcome the shortage of human organs, transgenic pigs have been generated that express human complement regulatory genes. This approach enables to overcome the hyperacute rejection response as shown by an average survival rate (40-90 days) of the immunosuppressed primate recipients receiving a heart from a transgenic pig. It is expected that transgenic pigs would be available as organ donors in the next 5-10 years. A major prerequisite, however, is the prevention of the potential transfer of pathogenic microorganisms, in particular porcine endogenous retroviruses (PERV). Improvements of the efficiency in the generation of transgenic pigs will be achieved by the use of genetically modified donor cells in nuclear transfer technology (cloning). 相似文献
18.
19.
20.
Strategies for Using eFSH for Superovulating Mares 总被引：1，自引：0，他引：1
Patrick M. McCue DVM PhD Melissa Patten BS David Denniston PhD Jason E. Bruemmer PhD Edward L. Squires PhD 《Journal of Equine Veterinary Science》2008,28(2):91-96
The standard treatment for superovulation of mares is to administer equine follicle-stimulating hormone (eFSH) for 4 to 5 days to stimulate multiple follicles and human chorionic gonadotropin (hCG) to induce synchronous ovulations. Objectives of this study were: (1) to determine whether a short-term (3-day) eFSH treatment protocol would result in similar ovulation and embryo recovery rates compared with the standard eFSH protocol; (2) to determine the efficacy of a decreasing dose of eFSH (step-down protocol) on ovulation rate and embryo recovery; (3) to compare the efficacy of hCG and recombinant equine luteinizing hormone (reLH) for inducing ovulation in FSH-treated mares; and (4) to compare embryo recovery rates and embryo size when mares are flushed at 6.5 or 7.0 days after ovulation. Forty light-horse mares were used in 2005 (experiment 1) and 20 different mares were used in 2006 (experiment 2). In experiment 1, mares were randomly assigned to one of three treatment groups: (1) untreated controls, (2) standard eFSH treatment (12.5 mg intramuscularly twice daily), and (3) 3-day eFSH treatment. In experiment 2, mares were randomly assigned to one of four treatments: (1) untreated controls, (2) standard eFSH protocol, (3) 3-day eFSH treatment, and (4) step-down eFSH treatment (12.5 mg twice daily day 1, 8.0 mg twice daily day 2, 4.0 mg twice daily day 3). Within each treatment, mares were given either hCG (2,500 IU) or equine LH (750 mg, EquiPure LH; reLH) to induce synchronized ovulations. Embryo recovery was performed either 6.5 or 7.0 days after ovulation. In experiment 1, numbers of preovulatory follicles and ovulations were less for mares in the 3-day treatment group than the standard group, but were greater than for controls. Embryo recovery per flush was higher in the standard group (2.6) than the 3-day eFSH treatment (0.8) or control groups (0.8). In experiment 2, the number of preovulatory follicles and number of ovulations were greater in the standard and 3-day treatment groups than in control and step-down groups. The percent embryo recovery per ovulation and mean embryo grade were similar for all groups; however, the embryo recovery per flush was higher for mares in the standard treatment than controls (1.3 vs 0.6) but was similar to the 3-day (1.1) and step-down (0.8) treatments. Embryo recovery was similar for flushes performed on days 6.5 and 7.0 post-ovulation. The percentage of control mares ovulating within 48 hours in response to hCG or reLH was similar. In contrast, a higher percentage of eFSH-treated mares ovulated within 48 hours in response to reLH than hCG (92% vs 71%). In both years, the 3-day eFSH treatment protocol resulted in a greater number of preovulatory follicles and a greater number of ovulations than untreated controls. Unfortunately, the increased ovulation rate for mares administered eFSH for 3 days did not result in a greater number of embryos recovered per flush in either year. Use of a step-down eFSH treatment protocol resulted in fewer preovulatory follicles, fewer ovulations, and fewer embryos as compared with the standard eFSH treatment. In conclusion, the standard eFSH treatment resulted in a greater embryo recovery rate per cycle than either the 3-day or step-down treatment protocols. Recombinant equine LH was more effective than hCG in causing ovulation in eFSH-treated mares. 相似文献